ClinicalTrials.gov
ClinicalTrials.gov Menu

HIV Disclosure and Medication Adherence, a Pilot Study (RSAD-VIH-11)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01621412
Recruitment Status : Completed
First Posted : June 18, 2012
Last Update Posted : December 22, 2015
Sponsor:
Collaborators:
Centre Hospitalier Universitaire Vaudois
Swiss HIV Cohort Study
Information provided by (Responsible Party):
Marie Schneider, Policlinique Médicale Universitaire

Study Description
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The investigators believe that disclosure of HIV status could influence medication adherence. If disclosure leads to social support, adherence could be improved. This study purpose is to assess correlation between disclosure and medication adherence, and to describe people whose HIV status has been disclosed to.

Condition or disease
HIV Infection

Detailed Description:

Pharmacists administer a questionnaire to each consecutive subject taking part in the adherence-enhancing program at the pharmacy of the Department of Ambulatory Care And Community Medicine in Lausanne. This questionnaire assesses disclosure, response to disclosure, and living situation.

Adherence is measured by electronic monitoring and pill count.


Study Design
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Observational
Estimated Enrollment : 120 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: HIV Disclosure and Medication Adherence, a Pilot Study
Study Start Date : April 2012
Actual Primary Completion Date : June 2013
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Groups and Cohorts
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Patient Adherence [ Time Frame: 30 days before survey ]
    Electronic monitoring of adherence during 30 days before survey


Secondary Outcome Measures :
  1. Patient Adherence [ Time Frame: 90 days before survey ]
    Electronic monitoring of adherence during 90 days before survey


Eligibility Criteria
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients enrolled in the adherence-enhancing program at ther pharmacy of Department of Ambulatory Care and Community Medicine in Lausanne
Criteria

Inclusion Criteria:

  • HIV Infection
  • Enrolled in the adherence-enhancing program

Exclusion Criteria:

  • Inclusion visit
  • Not french or english speaker
Contacts and Locations
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01621412


Locations
Switzerland
Policlinique Médicale Universitaire
Lausanne, Vaud, Switzerland, 1011
Sponsors and Collaborators
Policlinique Médicale Universitaire
Centre Hospitalier Universitaire Vaudois
Swiss HIV Cohort Study
Investigators
Principal Investigator: Marie-Paule Schneider, PhD Policlinique Médicale Universitaire
Principal Investigator: Aurélie Gertsch, PhD-Student Policlinique Médicale Universitaire
Study Chair: Olivier Bugnon, Professor Policlinique Médicale Universitaire
Study Chair: Matthias Cavassini, MD Centre Hospitalier Universitaire Vaudois
More Information
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Marie Schneider, Pharmacist, PhD, Policlinique Médicale Universitaire
ClinicalTrials.gov Identifier: NCT01621412     History of Changes
Other Study ID Numbers: RSAD-VIH-2011
First Posted: June 18, 2012    Key Record Dates
Last Update Posted: December 22, 2015
Last Verified: December 2015

Keywords provided by Marie Schneider, Policlinique Médicale Universitaire:
Medication Adherence
HIV infection
Disclosure

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
 Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases